Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 50,439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Behavioral Intervention, Group Therapy, Psilocybin, Questionnaire Administration; Behavioral · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Azacitidine, Sargramostim; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: Regorafenib; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Including Dallas, TX, Ocala, FL, Denver, CO, Florida

Conditions: Advanced Solid Tumors
Interventions: PX-866; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Aurora, Colorado • Houston, Texas

Conditions: Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: lenvatinib, everolimus; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Carlos, California

Conditions: Prostate Cancer
Interventions: [68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT; Drug · Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer, Peritoneal Cancer
Interventions: DCVac-L; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aplastic Anemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Juvenile Myelomonocytic Leukemia, Mastocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Waldenström Macroglobulinemia
Interventions: Fludarabine, Busulfan, Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplantation, Peripheral blood stem cell transplantation (PBSCT); Drug · Radiation · Biological + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sarcoma, Ewing's
Interventions: CP-751,871; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 9 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Rochester, Minnesota

Conditions: Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions: ASTX029, ASTX727; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumors
Interventions: bsi-201 + topotecan, bsi-201 + temozolomide, bsi-201 + gemcitabine, bsi-201 + carboplatin/paclitaxel; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: New Haven, Connecticut • Detroit, Michigan • New York, New York + 3 more

Conditions: Glioblastoma, Adult
Interventions: NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT); Device · Drug · Radiation
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Breast Cancer, Brain Metastases, Adult
Interventions: Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy; Drug · Radiation
Lead sponsor: Colette Shen; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Bowens Disease
Interventions: Imiquimod; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Endometrial Cancer
Interventions: Metformin, Letrozole, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 6
States / cities: Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas

Conditions: Vapors; Inhalation, Cancer, Volatile Organic Compounds
Interventions: Environmental educational campaign; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Non-small Cell Lung Cancer
Interventions: Trabedersen, Pembrolizumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Osteoarthritis Shoulder, Rheumatoid Arthritis, Oncology
Interventions: Not listed
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer
Interventions: 4D Conformal Image-Guided Partial Breast RT; Radiation
Lead sponsor: Yale University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: Recombinant Interleukin-12; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: TU2218 + KEYTRUDA® (Pembrolizumab); Drug
Lead sponsor: TiumBio Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: San Antonio, Texas • Tyler, Texas • Spokane, Washington

Conditions: COVID-19, Cancer
Interventions: Hydroxychloroquine, Placebo, Radiation therapy; Drug · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Active Rheumatoid Arthritis
Interventions: ELV001 25 mg, ELV001 75 mg, ELV001 125 mg, Placebo; Drug
Lead sponsor: Elevara Medicines Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 22
States / cities: Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 18 more

Search by objective public record fields.

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Phase I Trial of Oral PX-866

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

BESPOKE Study of ctDNA Guided Immunotherapy

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

Topical Imiquimod for Bowen's Disease of the Head and Neck

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Addressing Tetrachloroethylene Exposure in an Impacted Community

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)

4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer

Interleukin-12 in Treating Patients With Cancer in the Abdomen

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)